The successful transfer of the individual carrying this variant from insulin pump therapy to an oral short-acting meglitinide proves that she did not have type 1 diabetes but does not exclude the possibility of type 2 diabetes. The gene discussed is INS; the disease is type 2 diabetes mellitus.